Australian TGA approval typically follows 12 to 24 months after FDA approval, though Lilly may pursue simultaneous submissions
Pre-existing gastrointestinal disorders, particularly functional dyspepsia or irritable bowel syndrome, appear to predispose patients to more pronounced GI symptoms
doi: 10.13422/j.carol.carroll.nki.syfjx.20230941 186 WeiHZhaoRLiSDuoHHuoH
Emlenoflast and NT-0796 were announced safe and well-tolerated, suggesting promising clinical efficacy in adult patients [153,154,155, 192,193,194]
Additionally, the slower movement of food through your gut can cause temporary constipation, which further traps gas and increases bloating sensations
Use should be cautious and medically supervised in individuals with epilepsy, hypothyroidism, kidney issues, or those taking medications